ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer's Disease Diagnostics

The ALZpath Antibody is Integral to Advanced Blood Tests for Early Diagnosis of Alzheimer's Disease and is Widely Available on Research and Clinical Testing Platforms

CARLSBAD, Calif., April 7, 2025 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced it has been honored with the Bronze Edison Best New Product award.

ALZpath's pTau217 antibody, utilized in a wide range of commercially available blood tests, enables highly sensitive and accurate detection of pTau217, a key Alzheimer's disease pathology biomarker, well before symptoms appear.

Prior to the availability of blood tests such as those utilizing the ALZpath pTau217 biomarker to detect Alzheimer's disease, researchers and clinicians had to rely on positron emission tomography (PET) imaging and cerebrospinal fluid (CSF) testing, which are invasive, costly, and require specialized equipment and expertise to administer. As a result, these tests are difficult to make available at the scale required to meet growing demands, especially as promising new treatments are reaching the market.

"It is an honor to be named as a Bronze winner by the Edison Awards for our role in addressing the growing diagnostic needs of Alzheimer's disease patients and families," said Mike Banville, CEO and President of ALZpath. "Our solution comes at a critical time as cases of Alzheimer's disease and related dementias are expected to impact 153 million people worldwide by 2050 -- and yet the condition remains significantly under-diagnosed. By some estimates, more than seven million Americans* with mild cognitive impairment (MCI) over age 65 don't have a diagnosis, which means they can't get access to the latest trials or treatments. We aim to change that by licensing our pTau217 antibody to leading diagnostic companies and labs to accelerate and expand access to an early and accurate diagnosis for as many patients as possible."

Winning an Edison Award is a mark of distinction, honoring those who push the boundaries of innovation to solve global challenges and improve lives. Named after Thomas Edison (1847–1931), one of history's greatest inventors, the awards celebrate forward-thinking solutions and bold ideas that shape the future. ALZpath was selected from among thousands of submissions, rigorously evaluated on Concept, Value, and Impact by the Edison Awards Steering Committee and an independent panel of experts, including senior scientists, engineers, designers and business leaders.

"The ALZpath proprietary pTau217 antibody stood out as a groundbreaking advancement in the Advancements in Neurological Treatments category, demonstrating the power of innovation to create lasting impact," said Frank Bonafilia, Executive Director of the Edison Awards. "Our panel of judges was impressed by the ingenuity and leadership behind this innovation."

About ALZpath

ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. Its ALZpath pTau217 antibody, utilized in a wide range of commercially available blood tests transforming Alzheimer's disease research, diagnosis, treatment, and monitoring. To accelerate the development of new medicines and improve patient care for millions, ALZpath democratizes access to its proprietary antibody through licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact. ALZpath has been recognized as a Time Magazine Best Invention (2024) and Fast Company Most Innovative Company (2025). To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.

About The Edison Awards™

Established in 1987, the Edison Awards are dedicated to recognizing, honoring and fostering innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design and innovation. For more information, visit www.edisonawards.com.

ALZpath Media Contact
Nechama Rosengarten
[email protected]

SOURCE ALZpath, Inc.